Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines [0.03%]
欧洲肿瘤内科学会临床实践指南更新的肝细胞癌(HCC)治疗推荐
A Vogel,E Martinelli;ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org;ESMO Guidelines Committee
A Vogel
Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes? [0.03%]
高血清PD-1患者的免疫复合物与PD-1阻滞剂反应受损有关吗？
E Daveri,E Luison,V Vallacchi et al.
E Daveri et al.
T Baert,A Ferrero,J Sehouli et al.
T Baert et al.
Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically driven algorithm. Nowadays, platinum-based chemotherapy should be offered to all patie...
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I [0.03%]
mirvetuximab soravtansine对比化疗治疗铂类耐药性卵巢癌III期FORWARD I研究主要分析结果
K N Moore,A M Oza,N Colombo et al.
K N Moore et al.
Background: Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. The rand...
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies [0.03%]
omalizumab阻断可减轻免疫检查点抑制剂和抗HER2药物相关的瘙痒症状
D M Barrios,G S Phillips,A N Geisler et al.
D M Barrios et al.
Background: Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous pemphigoid, urticaria). In oncology, pruritus-associated cut...
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study [0.03%]
德国霍奇金病研究组HD18研究的亚组分析：正电子发射断层扫描指导下的升级BEACOPP方案治疗高级别结节型淋巴细胞为主型霍奇金淋巴瘤
D A Eichenauer,S Kreissl,I Bühnen et al.
D A Eichenauer et al.
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation [0.03%]
氟尿嘧啶治疗期间假性二氢嘧啶脱氢酶缺乏的误判是由尿嘧啶水平升高引起
F Thomas,M Maillard,M Launay et al.
F Thomas et al.
NTRK fusion in soft tissue sarcomas harboring MDM2/CDK4 amplification: three case reports [0.03%]
软组织肉瘤中MDM2/CDK4扩增患者的NTRK融合基因：3例报告
M Brahmi,A Dufresne,B Verret et al.
M Brahmi et al.
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs [0.03%]
新一代ALK酪氨酸激酶抑制剂治疗后患者的劳拉替尼血脑屏障穿透力及其对ALK阳性非小细胞肺癌的疗效研究
E Felip,A T Shaw,A Bearz et al.
E Felip et al.
Background: Lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has substantial activity against ALK-positive non-small-cell lung cancer (NSCLC). This ...